Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab

Breast Cancer Research and Treatment

Volumn 127, Issue 3, 2011, Pages 841-844

  Oliveira, Mafalda ^a   Braga, Sofia ^b   Passos Coelho, José Luís ^a   Fonseca, Ricardo ^a   Oliveira, João ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

HER2+ breast cancer; Intrathecal trastuzumab; Leptomeningeal carcinomatosis

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; LAPATINIB; LETROZOLE; METHOTREXATE; PREDNISOLONE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; AUTOPSY; BONE METASTASIS; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LIVER METASTASIS; LUMBAR PUNCTURE; LUNG METASTASIS; LYMPH NODE METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MENINGEAL CARCINOMATOSIS; MENINGITIS, LISTERIA; RECEPTOR, ERBB-2;

EID: 79958251618     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1417-2     Document Type: Article

References (17)

1. SA Grossman MJ Krabak 1999 Leptomeningeal carcinomatosis Cancer Treat Rev 25 103 119 10395835 10.1053/ctrv.1999.0119 1:STN:280:DyaK1Mzis1Cmuw%3D%3D (Pubitemid 29353669)
2. BC Pestalozzi D Zahrieh KN Price SB Holmberg J Lindtner J Collins D Crivellari MF Fey E Murray O Pagani E Simoncini M Castiglione-Gertsch RD Gelber AS Coates A Goldhirsch 2006 Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol 17 935 944 16603601 10.1093/annonc/mdl064 1:STN:280:DC%2BD283nslenuw%3D%3D (Pubitemid 43778983)
3. FC Bidard MN Guilhaume H Gauthier PH Cottu V Dieras JY Pierga 2009 Meningeal carcinomatosis in HER2-overexpressing breast cancers J Neurooncol 93 287 288 19139826 10.1007/s11060-008-9768-1 1:STN:280:DC%2BD1MzkslOktQ%3D%3D
4. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
5. K Yonemori K Tsuta M Ono C Shimizu A Hirakawa T Hasegawa Y Hatanaka Y Narita S Shibui Y Fujiwara 2010 Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer Cancer 116 302 308 19937674 10.1002/cncr.24735
6. MA Molina J Codony-Servat J Albanell F Rojo J Arribas J Baselga 2001 Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res 61 4744 4749 11406546 1:CAS:528:DC%2BD3MXks1Grtbo%3D (Pubitemid 32691885)
7. J Baselga EA Perez T Pienkowski R Bell 2006 Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer Oncologist 11 Suppl 1 4 12 16971734 10.1634/theoncologist.11-90001-4 1:CAS:528: DC%2BD28XhtFKqtr7N
8. K Yonemori K Tsuta M Ono C Shimizu A Hirakawa T Hasegawa Y Hatanaka Y Narita S Shibui Y Fujiwara 2009 Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer Cancer 116 302 308 10.1002/cncr.24735
9. HJ Stemmler M Schmitt A Willems H Bernhard N Harbeck V Heinemann 2007 Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anticancer Drugs 18 23 28 17159499 10.1097/01.cad. 0000236313.50833.ee 1:CAS:528:DC%2BD28Xht1yrt7bO (Pubitemid 44949792)
10. LR Laufman KF Forsthoefel 2001 Use of intrathecal trastuzumab in a patient with carcinomatous meningitis Clin Breast Cancer 2 235 11899418 1:STN:280:DC%2BD387mvVagtw%3D%3D (Pubitemid 33085772)
11. M Colozza E Minenza S Gori D Fenocchio C Paolucci C Aristei P Floridi 2009 Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab Cancer Chemother Pharmacol 63 1157 1159 18987856 10.1007/s00280-008-0859-7
12. Shojima K, Suzuki E, Saito K, Sekine S, Kitagawa D, Aruga T, Saji S, Kuro K (2008) Application of intrathecal trastuzumab for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. J Clin Oncol 26 (May 20 suppl; abstr 1138)
13. C Ferrario A Davidson N Bouganim R Aloyz LC Panasci 2009 Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer Ann Oncol 20 792 795 19223574 10.1093/annonc/mdp019 1:STN:280:DC%2BD1M3jt1Ojuw%3D%3D
14. O Mir S Ropert J Alexandre F Lemare F Goldwasser 2008 High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer Ann Oncol 19 1978 1980 18845838 10.1093/annonc/mdn654 1:STN:280:DC%2BD1cnosFeluw%3D%3D
15. C Platini J Long S Walter 2006 Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab Lancet Oncol 7 778 780 16945774 10.1016/S1470-2045(06)70864-6 (Pubitemid 44283672)
16. HJ Stemmler K Mengele M Schmitt N Harbeck D Laessig KA Herrmann P Schaffer V Heinemann 2008 Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report Anticancer Drugs 19 832 836 18690096 10.1097/CAD.0b013e32830b58b0 1:CAS:528:DC%2BD1cXpsFKqu7o%3D
17. HJ Stemmler M Schmitt N Harbeck A Willems H Bernhard D Lassig S Schoenberg V Heinemann 2006 Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer Oncol Rep 15 1373 1377 16596213 1:CAS:528:DC%2BD28XksFKiurY%3D